Staidson BioPharma Inc. in San Francisco is a subsidiary of Staidson (Beijing) Biopharmaceutical Company Ltd.. Staidson (Beijing) was established in 2002 in the Beijing Economic and Technology Development Area (BDA). Finished its IPO on April 15, 2011 at Growth Enterprise Market in Shenzhen Stock Market, China (No. 300204). Currently we have employee 830 totals, 150 for R&D and 430 for Sales and marketing. Five products have been approved for Chinese market, including Patent biological medicine, chemical medicine, and generic chemical drug. We are looking for License-in opportunity for new biological product and technologies for Chinese marketing or co-development globally.
Staidson Overview -Founded in 2002, and went public (Stock No. 300204) in China Stock Market in 2011. -Total 830 employee, 150 of R&D and 430 of sales and marketing -Pipelines in biology drugs, small molecule drugs, gene therapy and herb drugs. -Loacated in the Beijing Economic and Technology Development Area (BDA) -New drug manufacuturing facility in production in 2012 -Currently in China market and targeting international market in near future.